Suppr超能文献

新型含酰基脯氨酰酪氨酸化合物GZR - 123与舒必利的抗精神病活性及辨别刺激效应比较

Comparison of antipsychotic activity and discriminative stimulus effects of the novel acylprolyltyrosine containing compound, GZR-123, and sulpiride.

作者信息

Asmakova L S, Kalinina T S, Ostrovskaya R U, Gudasheva T A, Zaitseva N I, Bondarenko N A, Voronina T A, Seredenin S B

机构信息

Institute of Pharmacology of RAMS, Moscow, Russia.

出版信息

Pharmacol Biochem Behav. 1999 Oct;64(2):359-62. doi: 10.1016/s0091-3057(99)00048-9.

Abstract

The present experiment has been performed to determine the pharmacological profile of a newly synthesized systematically active prolyltyrosine containing compound, caproyl-L-Pro-L-Tyr methyl ester (GZR-123), and to compare it with that of the standard atypical benzamide neuroleptic, sulpiride. GZR-123 demonstrated antagonistic activity on apomorphine-induced climbing and on L-DOPA-dependent extrapolatory behavior in dose ranging between 0.4-4.0 mg/kg i.p.. It did not provoke a cataleptogenic effect or lethality, even at doses much higher than those causing antidopamine effects (more than 500 mg/kg). The effective doses of sulpiride in the above-listed antidopamine tests were shown to be 17.5 and 16.0 mg/kg i.p. correspondingly. Although these doses of sulpiride did not demonstrate cataleptogenic effects, an increase of the dose level to 120 mg/kg induced pronounced catalepsy. Both GZR-123 (6 mg/kg) and sulpiride (40 and 60 mg/kg) were investigated by training rats to discriminate each of them from saline in a two-lever, water-reinforcement operant procedure. Both GZR-123 and sulpiride demonstrated weak discriminability in this task. GZR-123 increased drug-associated lever selection when administered in doses of 2 and 6 mg/kg, for sulpirirde these doses were demonstrated to be 25-60 mg/kg. In contrast to GZR-123, which did not provoke a sedative effect, sulpiride in higher discriminable doses caused sedation, which stems probably from the motivational, but not from the motor deficit.

摘要

本实验旨在确定一种新合成的具有全身活性的含脯氨酰酪氨酸化合物己酰-L-脯氨酰-L-酪氨酸甲酯(GZR-123)的药理学特性,并将其与标准非典型苯甲酰胺类抗精神病药物舒必利进行比较。GZR-123腹腔注射剂量在0.4-4.0mg/kg之间时,对阿扑吗啡诱导的攀爬行为和左旋多巴依赖性外推行为具有拮抗活性。即使在远高于引起抗多巴胺作用的剂量(超过500mg/kg)下,它也不会引发僵住效应或致死性。舒必利在上述抗多巴胺试验中的有效剂量分别为腹腔注射17.5和16.0mg/kg。虽然这些剂量的舒必利未表现出僵住效应,但剂量增加到120mg/kg时会诱发明显的僵住症。通过训练大鼠在双杠杆、水强化操作性程序中区分GZR-123(6mg/kg)和舒必利(40和60mg/kg)与生理盐水,对它们进行了研究。在这项任务中,GZR-123和舒必利的辨别能力都较弱。GZR-123以2和6mg/kg的剂量给药时会增加与药物相关的杠杆选择,舒必利的这些剂量为25-60mg/kg。与未引发镇静作用的GZR-123不同,较高可辨别剂量的舒必利会引起镇静,这可能源于动机因素,而非运动功能缺陷。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验